Abstract
Chronic liver and kidney diseases are among the most fearful pathologies affecting an increasing number of people, having severe consequences on life quality. Although much progress has been made in recent years, availability of cost-effective and innovative therapies is still an unmet medical need. One of the major challenges in the therapy of liver and kidney diseases is to selectively deliver drugs to achieve therapeutically relevant concentration in the target organ, in order to decrease the amount of drug needed and to reduce unwanted side effects. In this review we summarize recent advances in selective drug targeting to liver or to kidney including cell-selective therapeutic approaches as well. We pay special attention to plant-derived bioactive molecules which constitute promising tools for the treatment of chronic liver and kidney diseases. We discuss cellular, subcellular and molecular mechanisms underlying the observed pharmacological effects of plant-derived drugs and give an overview of formulations, which can increase therapeutic effectiveness of these biomolecules in the treatment of chronic liver and kidney disorders.
Keywords: liver fibrosis, kidney fibrosis, plant-derived biomolecules, drug delivery.
Current Pharmaceutical Design
Title:Plant-Derived Biomolecules and Drug Delivery Systems in the Treatment of Liver and Kidney Diseases
Volume: 22 Issue: 35
Author(s): Anca Hermenean, Claudia Smeu, Sami Gharbia, Istvan A. Krizbai and Aurel Ardelean
Affiliation:
Keywords: liver fibrosis, kidney fibrosis, plant-derived biomolecules, drug delivery.
Abstract: Chronic liver and kidney diseases are among the most fearful pathologies affecting an increasing number of people, having severe consequences on life quality. Although much progress has been made in recent years, availability of cost-effective and innovative therapies is still an unmet medical need. One of the major challenges in the therapy of liver and kidney diseases is to selectively deliver drugs to achieve therapeutically relevant concentration in the target organ, in order to decrease the amount of drug needed and to reduce unwanted side effects. In this review we summarize recent advances in selective drug targeting to liver or to kidney including cell-selective therapeutic approaches as well. We pay special attention to plant-derived bioactive molecules which constitute promising tools for the treatment of chronic liver and kidney diseases. We discuss cellular, subcellular and molecular mechanisms underlying the observed pharmacological effects of plant-derived drugs and give an overview of formulations, which can increase therapeutic effectiveness of these biomolecules in the treatment of chronic liver and kidney disorders.
Export Options
About this article
Cite this article as:
Hermenean Anca, Smeu Claudia, Gharbia Sami, Krizbai A. Istvan and Ardelean Aurel, Plant-Derived Biomolecules and Drug Delivery Systems in the Treatment of Liver and Kidney Diseases, Current Pharmaceutical Design 2016; 22 (35) . https://dx.doi.org/10.2174/1381612822666160726125157
DOI https://dx.doi.org/10.2174/1381612822666160726125157 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface
Current Molecular Medicine Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Antioxidant Effects of Chalcones during the Inflammatory Response: An Overall Review
Current Medicinal Chemistry A Mechanistic Rationale for PDE-4 Inhibitors to Treat Residual Cognitive Deficits in Acquired Brain Injury
Current Neuropharmacology GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Current Hypertension Reviews Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Neutrophil MiRNA-128-3p is Decreased During Active Phase of Granulomatosis with Polyangiitis
Current Genomics Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Exercise and Cardiac Preconditioning Against Ischemia Reperfusion Injury
Current Cardiology Reviews An Optimal Combination of Chemically Pure Compounds from <i>Salvia miltiorrhiza</i> for Inhibiting Cell Proliferation
Cardiovascular & Hematological Agents in Medicinal Chemistry Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury
Current Neurovascular Research Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design